

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

---

BELCHER PHARMACEUTICALS, LLC,	)	
	)	
Plaintiff,	)	C.A. No. 17-cv-775-LPS
	)	
v.	)	
	)	
HOSPIRA, INC.	)	
	)	
Defendant.	)	
	)	

---

**FINAL JUDGMENT**

This action, having come to trial before the Court, Honorable Leonard P. Stark, Chief District Judge presiding, the issues having been heard and a decision having been rendered: **IT IS ORDERED AND ADJUDGED** this 3rd day of April, 2020, for the reasons set forth in the Court’s Opinion and Order dated March 31, 2020 (D.I. 244, 245), that:

1. Judgment shall be and is hereby entered in favor of Defendant Hospira Inc. (“Hospira”) and against Plaintiff Belcher Pharmaceuticals, LLC (“Belcher”) on Belcher’s Count I in its Complaint dated June 16, 2017, for infringement of U.S. Patent No. 9,283,197 (“the ’197 patent”). (D.I 1.)

2. Judgment shall be and is hereby entered in favor of Hospira and against Belcher on Hospira’s Counterclaim Counts I, II, III, and IV in its First Amended Answer and Counterclaims, dated February 11, 2019, for (1) declaratory judgment of noninfringement of the ’197 patent; (2) declaratory judgment of invalidity of the ’197 patent; (3) unenforceability of the ’197 patent for inequitable conduct; and (4) invalidity of the ’197 patent for improper inventorship.

  
UNITED STATES DISTRICT JUDGE

4/3/2020